NASDAQ:ORKA Oruka Therapeutics (ORKA) Stock Price, News & Analysis $82.11 +4.83 (+6.25%) Closing price 04:00 PM EasternExtended Trading$82.18 +0.08 (+0.09%) As of 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsInsider TradesNews and TrendsOwnershipSEC FilingsShort Interest About Oruka Therapeutics Stock (NASDAQ:ORKA) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Oruka Therapeutics alerts:Sign Up Key Stats Today's Range$77.00▼$82.2450-Day Range$77.28▼$113.0852-Week Range$24.31▼$115.51Volume1.21 million shsAverage Volume1.10 million shsMarket Capitalization$5.44 billionP/E RatioN/ADividend YieldN/APrice Target$128.91Consensus RatingModerate Buy Company Overview Oruka Therapeutics, Inc. (NASDAQ: ORKA) is a clinical-stage biopharmaceutical company developing long-acting antibody therapies for immune-mediated diseases. The company’s approach is designed to extend the duration of treatment and potentially reduce the frequency of dosing for patients with chronic inflammatory conditions. Oruka’s pipeline includes ORKA-001 and ORKA-002, next-generation monoclonal antibodies targeting interleukin-23 (IL-23), a cytokine involved in several autoimmune and inflammatory diseases. The programs are being developed initially for conditions such as plaque psoriasis, with potential applications in other immune-mediated disorders. Oruka became a publicly traded company through a business combination with ARCA biopharma, Inc. in 2024, after which ARCA adopted the Oruka Therapeutics name and its shares began trading under the ORKA symbol. The company is focused on advancing its pipeline through clinical development and regulatory processes for patients in the United States and potentially other markets.AI Generated. May Contain Errors. Read More Oruka Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks63rd Percentile Overall ScoreORKA MarketRank™: Oruka Therapeutics scored higher than 63% of companies evaluated by MarketBeat, and ranked 303rd out of 881 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.4 / 5Analyst RatingModerate Buy Consensus RatingOruka Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.82, and is based on no strong buy ratings, 10 buy ratings, no hold ratings, and 1 sell rating.Upside PotentialOruka Therapeutics has a consensus price target of $128.91, representing about 57.0% upside from its current price of $82.11.Amount of Analyst CoverageOruka Therapeutics has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Oruka Therapeutics' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Oruka Therapeutics are expected to decrease in the coming year, from ($2.42) to ($2.93) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Oruka Therapeutics is -40.45, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Oruka Therapeutics is -40.45, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioOruka Therapeutics has a P/B Ratio of 8.47. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Oruka Therapeutics' valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted15.05% of the float of Oruka Therapeutics has been sold short.Short Interest Ratio / Days to CoverOruka Therapeutics has a short interest ratio ("days to cover") of 11.61, which indicates bearish sentiment.Change versus previous monthShort interest in Oruka Therapeutics has recently decreased by 2.19%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldOruka Therapeutics does not currently pay a dividend.Dividend GrowthOruka Therapeutics does not have a long track record of dividend growth. News and Social Media3.5 / 5News Sentiment0.64 News SentimentOruka Therapeutics has a news sentiment score of 0.64. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.39 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 8 news articles for Oruka Therapeutics this week, compared to 5 articles on an average week.Search InterestOnly 2 people have searched for ORKA on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.MarketBeat Follows3 people have added Oruka Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 50% compared to the previous 30 days. Company Ownership2.1 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Oruka Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $13,619,306.00 in company stock.Percentage Held by Insiders23.49% of the stock of Oruka Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions56.44% of the stock of Oruka Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Oruka Therapeutics' insider trading history. Receive ORKA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Oruka Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. ORKA Stock News HeadlinesORKA-002 Phase 1 Milestone: What Oruka’s First-in-Human Trial Means for InvestorsOctober 9 at 12:31 PM | tipranks.comOruka Therapeutics, Inc. (NASDAQ:ORKA) Stock Has Consensus Target Price of $128.91October 8 at 2:28 AM | americanbankingnews.comMy top 3 AI picks for the next decadeAlexander Green bought Apple in 1996, recommended Nvidia at a split-adjusted 66 cents in 2004, and picked up Amazon and Netflix under $3 per share in 2005. Now the chief investment strategist at The Oxford Club has identified three AI stocks he believes could be the most profitable investments of the next decade.October 9 at 1:00 AM | The Oxford Club (Ad)Oruka Therapeutics (NASDAQ:ORKA) CEO Lawrence Otto Klein Sells 25,000 Shares of StockOctober 3, 2026 | americanbankingnews.comOruka Therapeutics (NASDAQ:ORKA) CEO Sells $2,090,500.00 in StockOctober 3, 2026 | insidertrades.comAnalysts Offer Insights on Healthcare Companies: Oruka Therapeutics (ORKA) and Co-Diagnostics (CODX)September 25, 2026 | theglobeandmail.comInsider Selling: Oruka Therapeutics (NASDAQ:ORKA) SVP Sells $51,034.75 in StockSeptember 22, 2026 | insidertrades.comOruka Therapeutics (NASDAQ:ORKA) SVP Sells 560 SharesSeptember 16, 2026 | insidertrades.comSee More Headlines ORKA Stock Analysis - Frequently Asked Questions How have ORKA shares performed this year? Oruka Therapeutics' stock was trading at $30.31 at the beginning of the year. Since then, ORKA stock has increased by 170.9% and is now trading at $82.11. How were Oruka Therapeutics' earnings last quarter? Oruka Therapeutics, Inc. (NASDAQ:ORKA) released its quarterly earnings results on Monday, August, 10th. The company reported ($0.55) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.51) by $0.04. Who are Oruka Therapeutics' major shareholders? Oruka Therapeutics' top institutional investors include GAMMA Investing LLC. Insiders that own company stock include Venrock Healthcare Capital Par, Fairmount Funds Management Llc, Lawrence Otto Klein, Carl Dambkowski, Joana Goncalves and Arjun Agarwal. View institutional ownership trends. How do I buy shares of Oruka Therapeutics? Shares of ORKA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Oruka Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Oruka Therapeutics investors own include Astria Therapeutics (ATXS), Aldeyra Therapeutics (ALDX), Black Diamond Therapeutics (BDTX), Energy Transfer (ET), Heron Therapeutics (HRTX), Skye Bioscience (SKYE) and NuScale Power (SMR). Company Calendar Last Earnings8/10/2026Today10/09/2026Next Earnings (Estimated)11/11/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (17m+) 1-Year History Oct 25 Jan 26 Apr 26 Jul 26 Oct 26 ORKA's financial health is in the Green zone, according to TradeSmith. ORKA has been in this zone for over 17 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:ORKA Previous SymbolNASDAQ:ORKA CIK907654 Webwww.orukatx.com Phone(650) 606-7910Fax720-208-9261Employees68Year FoundedN/APrice Target and Rating Average Price Target for Oruka Therapeutics$128.91 High Price Target$200.00 Low Price Target$45.00 Potential Upside/Downside+57.0%Consensus RatingModerate Buy Rating Score (0-4)2.82 Research Coverage11 Analysts Profitability EPS (Trailing Twelve Months)($2.03) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$105.43 million Net MarginsN/A Pretax MarginN/A Return on Equity-21.65% Return on Assets-20.88% Debt Debt-to-Equity RatioN/A Current Ratio38.51 Quick Ratio38.51 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$9.69 per share Price / Book8.47Miscellaneous Outstanding Shares66,210,000Free Float50,657,000Market Cap$5.44 billion OptionableN/A Beta-0.37 7 Stocks That Could Lead the Next Market BoomTesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.Get This Free Report This page (NASDAQ:ORKA) was last updated on 10/9/2026 by MarketBeat.com Staff. From Our PartnersALERT: Drop these 5 stocks before the market opens tomorrow!The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...Weiss Ratings | SponsoredTrump's New DollarPorter Stansberry says President Trump has signed an executive order initiating what he calls a full U.S. doll...Porter & Company | SponsoredSmall Colorado Company (Backed by Sam Altman) Could Save U.S. Power GridA small Colorado company has secured rights to technology that could prevent the U.S. public power grid from c...Altimetry | SponsoredReady to give options a try? Your first trade (Ticker included) -INSIDETired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...Base Camp Trading | SponsoredThe end may be near for these iconic stocksMarc Chaikin, founder of Chaikin Analytics, says two forces - AI disruption and fracturing global trade - are ...Chaikin Analytics | SponsoredLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...InvestorPlace | SponsoredHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...Stansberry Research | SponsoredHere’s Why Trump Won’t End The Iran WarTrump has called an Iran deal close 38 times since the war began, yet the fighting keeps flaring back up. O...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Oruka Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Oruka Therapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
